Opinion|Videos|March 13, 2026
Resistance mechanisms in EGFR-Mutated NSCLC
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss resistance mechanisms in EGFR-mutated NSCLC.
Advertisement
Episodes in this series
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, review both on-target and off-target resistance mechanisms that emerge during EGFR-directed therapy in EGFR-mutated NSCLC. Vokes explains how secondary EGFR mutations, MET amplification, and histologic transformation contribute to therapeutic failure. Devarakonda discusses the clinical importance of comprehensive molecular profiling to guide subsequent treatment selection.
Advertisement
Related to this article
Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.
Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.
Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.
The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
4
Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer
5